杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/10/31 | 1,499 | 1,519 | 1,497 | 1,517 | +18 | +1.2% | 75,800 |
| 2024/10/30 | 1,488 | 1,504 | 1,488 | 1,499 | +7 | +0.5% | 136,400 |
| 2024/10/29 | 1,487 | 1,496 | 1,483 | 1,492 | +3 | +0.2% | 46,800 |
| 2024/10/28 | 1,480 | 1,495 | 1,472 | 1,489 | +14 | +0.9% | 47,900 |
| 2024/10/25 | 1,487 | 1,487 | 1,468 | 1,475 | -10 | -0.7% | 102,700 |
| 2024/10/24 | 1,493 | 1,498 | 1,484 | 1,485 | -16 | -1.1% | 87,100 |
| 2024/10/23 | 1,497 | 1,503 | 1,493 | 1,501 | +4 | +0.3% | 69,100 |
| 2024/10/22 | 1,520 | 1,520 | 1,495 | 1,497 | -20 | -1.3% | 56,400 |
| 2024/10/21 | 1,522 | 1,525 | 1,515 | 1,517 | +1 | +0.1% | 53,700 |
| 2024/10/18 | 1,508 | 1,523 | 1,506 | 1,516 | +6 | +0.4% | 93,100 |
| 2024/10/17 | 1,502 | 1,517 | 1,502 | 1,510 | +9 | +0.6% | 46,500 |
| 2024/10/16 | 1,493 | 1,511 | 1,485 | 1,501 | ±0 | ±0% | 87,900 |
| 2024/10/15 | 1,505 | 1,511 | 1,495 | 1,501 | -3 | -0.2% | 121,200 |
| 2024/10/11 | 1,505 | 1,518 | 1,503 | 1,504 | -13 | -0.9% | 62,400 |
| 2024/10/10 | 1,520 | 1,520 | 1,508 | 1,517 | +2 | +0.1% | 30,000 |
| 2024/10/09 | 1,513 | 1,522 | 1,506 | 1,515 | +2 | +0.1% | 29,600 |
| 2024/10/08 | 1,521 | 1,525 | 1,510 | 1,513 | -18 | -1.2% | 56,500 |
| 2024/10/07 | 1,541 | 1,541 | 1,527 | 1,531 | +1 | +0.1% | 52,900 |
| 2024/10/04 | 1,523 | 1,536 | 1,522 | 1,530 | +3 | +0.2% | 48,500 |
| 2024/10/03 | 1,528 | 1,535 | 1,518 | 1,527 | +14 | +0.9% | 73,400 |
| 2024/10/02 | 1,506 | 1,518 | 1,500 | 1,513 | +7 | +0.5% | 85,400 |
| 2024/10/01 | 1,514 | 1,514 | 1,499 | 1,506 | -14 | -0.9% | 117,500 |
| 2024/09/30 | 1,506 | 1,522 | 1,504 | 1,520 | -12 | -0.8% | 84,400 |
| 2024/09/27 | 1,540 | 1,547 | 1,530 | 1,532 | -30 | -1.9% | 74,300 |
| 2024/09/26 | 1,542 | 1,564 | 1,538 | 1,562 | +33 | +2.2% | 165,300 |
| 2024/09/25 | 1,525 | 1,535 | 1,514 | 1,529 | +7 | +0.5% | 148,300 |
| 2024/09/24 | 1,519 | 1,528 | 1,508 | 1,522 | +17 | +1.1% | 65,500 |
| 2024/09/20 | 1,513 | 1,522 | 1,497 | 1,505 | -1 | -0.1% | 156,300 |
| 2024/09/19 | 1,513 | 1,519 | 1,504 | 1,506 | -5 | -0.3% | 56,400 |
| 2024/09/18 | 1,516 | 1,518 | 1,498 | 1,511 | +5 | +0.3% | 78,900 |
| 2024/09/17 | 1,532 | 1,532 | 1,497 | 1,506 | -9 | -0.6% | 87,700 |
| 2024/09/13 | 1,517 | 1,519 | 1,506 | 1,515 | -5 | -0.3% | 108,700 |
| 2024/09/12 | 1,528 | 1,541 | 1,512 | 1,520 | +7 | +0.5% | 87,800 |
| 2024/09/11 | 1,540 | 1,540 | 1,509 | 1,513 | -21 | -1.4% | 88,900 |
| 2024/09/10 | 1,541 | 1,558 | 1,534 | 1,534 | -19 | -1.2% | 77,800 |
| 2024/09/09 | 1,550 | 1,555 | 1,532 | 1,553 | -7 | -0.4% | 90,000 |
| 2024/09/06 | 1,581 | 1,581 | 1,556 | 1,560 | -21 | -1.3% | 88,900 |
| 2024/09/05 | 1,588 | 1,597 | 1,567 | 1,581 | -6 | -0.4% | 90,200 |
| 2024/09/04 | 1,601 | 1,616 | 1,584 | 1,587 | -34 | -2.1% | 117,000 |
| 2024/09/03 | 1,614 | 1,626 | 1,614 | 1,621 | +7 | +0.4% | 31,300 |
| 2024/09/02 | 1,625 | 1,630 | 1,606 | 1,614 | -10 | -0.6% | 78,000 |
| 2024/08/30 | 1,615 | 1,628 | 1,615 | 1,624 | +9 | +0.6% | 53,300 |
| 2024/08/29 | 1,623 | 1,630 | 1,613 | 1,615 | -19 | -1.2% | 35,700 |
| 2024/08/28 | 1,621 | 1,634 | 1,619 | 1,634 | +1 | +0.1% | 25,900 |
| 2024/08/27 | 1,632 | 1,637 | 1,622 | 1,633 | +15 | +0.9% | 33,000 |
| 2024/08/26 | 1,618 | 1,623 | 1,610 | 1,618 | -14 | -0.9% | 48,500 |
| 2024/08/23 | 1,628 | 1,638 | 1,625 | 1,632 | +11 | +0.7% | 52,500 |
| 2024/08/22 | 1,635 | 1,636 | 1,617 | 1,621 | -14 | -0.9% | 44,500 |
| 2024/08/21 | 1,621 | 1,637 | 1,620 | 1,635 | +4 | +0.2% | 43,600 |
| 2024/08/20 | 1,615 | 1,638 | 1,615 | 1,631 | +18 | +1.1% | 51,600 |
101～
150
件表示中 / 3671件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 145,400円 | +3.2% | +4.5% | 3.58% | 16.71倍 | 0.64倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 持田薬 | 309,500円 | +3.0% | +27.5% | 2.58% | 19.60倍 | 0.85倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| ジーエヌアイ | 192,800円 | +21.7% | +999.9% | 0.00% | 8.03倍 | 2.66倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| 栄研化 | 220,400円 | +0.4% | -8.4% | 2.40% | 28.30倍 | 1.61倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ネクセラファーマ | 85,200円 | +22.8% | - | 0.00% | 69.61倍 | 1.12倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム
